Skip to main content
Top
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Ionizing Radiation | Editorial

Immune radiobiology

Author: Claire Vanpouille-Box

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Excerpt

We are thrilled to announce the launch of a new section in the Journal of Translational Medicine entitled “Immune RadioBiology”. This section is interested in innovative research that investigate the crosstalk between ionizing radiations (IR), the tumor microenvironment (TME) and host immunity. Studies considered for publication include (but not limited to) those investigating the mechanisms of radiation-induced anti-tumor immune responses, the immune-stimulatory and immuno-suppressive properties of ionizing radiation from all sources (X-rays, FLASH-RT, protons, carbon ion and radionuclides), biomarkers predictive of immune response, immune escape mechanisms elicited by IR and radioresistance. Importantly, we are welcoming translational and clinical studies assessing the combination of IR with immunotherapies (IT) with an emphasis on clinical response and outcome. …
Literature
1.
go back to reference Stone HB, Peters LJ, Milas L. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst. 1979;63(5):1229–35.PubMed Stone HB, Peters LJ, Milas L. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst. 1979;63(5):1229–35.PubMed
3.
go back to reference De Martino M, et al. Exploiting radiation therapy to restore immune reactivity of glioblastoma. Front Oncol. 2021;11:1530.CrossRef De Martino M, et al. Exploiting radiation therapy to restore immune reactivity of glioblastoma. Front Oncol. 2021;11:1530.CrossRef
4.
go back to reference Demaria S, et al. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? J Immunother Cancer. 2021;9(4):e002038.CrossRef Demaria S, et al. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? J Immunother Cancer. 2021;9(4):e002038.CrossRef
5.
go back to reference Obeid M, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54–61.CrossRef Obeid M, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54–61.CrossRef
6.
go back to reference Apetoh L, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–9.CrossRef Apetoh L, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–9.CrossRef
7.
go back to reference Golden EB, et al. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology. 2014;3:e28518.CrossRef Golden EB, et al. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology. 2014;3:e28518.CrossRef
8.
go back to reference Zheng W, et al. RIG-I-Like receptor LGP2 is required for tumor control by radiotherapy. Cancer Res. 2020;80(24):5633–41.CrossRef Zheng W, et al. RIG-I-Like receptor LGP2 is required for tumor control by radiotherapy. Cancer Res. 2020;80(24):5633–41.CrossRef
9.
go back to reference Deng L, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41(5):843–52.CrossRef Deng L, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41(5):843–52.CrossRef
10.
go back to reference Vanpouille-Box C, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.CrossRef Vanpouille-Box C, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.CrossRef
11.
go back to reference Formenti SC, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24(12):1845–51.CrossRef Formenti SC, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24(12):1845–51.CrossRef
12.
go back to reference Rudqvist NP, et al. Radiotherapy and CTLA-4 blockade shape the TCR repertoire of tumor-infiltrating T cells. Cancer Immunol Res. 2018;6(2):139–50.CrossRef Rudqvist NP, et al. Radiotherapy and CTLA-4 blockade shape the TCR repertoire of tumor-infiltrating T cells. Cancer Immunol Res. 2018;6(2):139–50.CrossRef
13.
go back to reference Barcellos-Hoff MH, et al. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest. 1994;93(2):892–9.CrossRef Barcellos-Hoff MH, et al. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest. 1994;93(2):892–9.CrossRef
14.
go back to reference De Martino M, et al. Activin A promotes regulatory T-cell-mediated immunosuppression in irradiated breast cancer. Cancer Immunol Res. 2021;9(1):89–102.CrossRef De Martino M, et al. Activin A promotes regulatory T-cell-mediated immunosuppression in irradiated breast cancer. Cancer Immunol Res. 2021;9(1):89–102.CrossRef
16.
go back to reference Twyman-Saint Victor C, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–7.CrossRef Twyman-Saint Victor C, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–7.CrossRef
17.
go back to reference Gorin JB, et al. Antitumor immunity induced after alpha irradiation. Neoplasia. 2014;16(4):319–28.CrossRef Gorin JB, et al. Antitumor immunity induced after alpha irradiation. Neoplasia. 2014;16(4):319–28.CrossRef
18.
go back to reference Vanpouille-Box C, et al. Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with (188)Re-lipid nanocapsules. Biomaterials. 2011;32(28):6781–90.CrossRef Vanpouille-Box C, et al. Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with (188)Re-lipid nanocapsules. Biomaterials. 2011;32(28):6781–90.CrossRef
19.
go back to reference Montay-Gruel P, et al. Hypofractionated FLASH-RT as an effective treatment against glioblastoma that reduces neurocognitive side effects in mice. Clin Cancer Res. 2021;27(3):775–84.CrossRef Montay-Gruel P, et al. Hypofractionated FLASH-RT as an effective treatment against glioblastoma that reduces neurocognitive side effects in mice. Clin Cancer Res. 2021;27(3):775–84.CrossRef
Metadata
Title
Immune radiobiology
Author
Claire Vanpouille-Box
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-02928-w

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.